Skip to main content
OpenTrials
Completed

NCT Number: NCT03609775

A Study to Investigate the Drug-drug Interactions Between ACT-541468 and Ethanol in Healthy Subjects

A study to investigate the drug-drug interactions between ACT-541468 and ethanol in healthy subjects

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

18 year–45 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Centre For Human Drug Research

Leiden, 2333, Netherlands

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Signed informed consent prior to any study-mandated procedure.
  • Healthy male and female subjects aged between 18 and 45 years (inclusive) at screening.
  • Women of childbearing potential must have a negative serum pregnancy test at screening and a negative urine pregnancy test on Day 1 pre-dose of each treatment period. They must consistently and correctly use a reliable method of contraception, be sexually inactive, or have a vasectomized partner.
  • Women of non-childbearing potential (i.e., postmenopausal).
  • Body mass index of 18.0 to 32.0 kg/m2 (inclusive) at screening.
  • Healthy on the basis of medical history, physical examination, cardiovascular assessments and serology and laboratory tests.
  • Previous experience with alcohol consumption and, therefore, familiar with the effects of alcohol.

Exclusion criteria

  • Pregnant or lactating women.
  • Any circumstances or conditions, which, in the opinion of the investigator, may affect full participation in the study or compliance with the protocol.
  • Excessive caffeine consumption, defined as ≥ 800 mg per day at screening.
  • Nicotine intake within 3 months prior to screening and inability to refrain from nicotine intake from screening until End-of-Study (EOS).
  • Previous treatment with any prescribed medications (including vaccines) or over-the-counter (OTC) medications (including herbal medicines such as St John's Wort, homeopathic preparations, vitamins, and minerals) within 2 weeks prior to first study treatment administration.
  • History or clinical evidence of alcoholism or drug abuse.
  • History of regular alcohol consumption within 6 months of the study defined as an average weekly intake of more than 21 units or an average daily intake of more than 3 units (males), or defined as an average weekly intake of more than 14 units or an average daily intake of more than 2 units (females).
  • Individuals of Asian descent or other individuals reporting ethanol intolerance.
  • Modified Swiss Narcolepsy Scale total score < 0 at screening or history of narcolepsy or cataplexy.

Treatment and study plan

ACT-541468

Drug

One tablet of 50 mg ACT-541468 will be administered orally.

ACT-541468 placebo

Other

Matching ACT-541468 placebo will be administered orally as 1 tablet.

Ethanol 10%

Other

Ethanol 10% w/v solution in 5% glucose will be administered i.v. for 5 h and clamped at an ethanol level of 0.6 g/L.

Ethanol Placebo

Other

Matching placebo for the ethanol infusion (i.e., 5% glucose solution) will be administered i.v. for 5 h.

Primary outcomes

  1. Change from baseline for saccadic peak velocity (degrees/sec) to assess sedation

    Time frame: Several timepoints on Day 1; for up to 24 hours post-dose

Other outcomes

  1. Change from baseline for smooth pursuit (%) to assess eye movement coordination and attention

    Time frame: Several timepoints on Day 1; for up to 24 hours post-dose

  2. Change from baseline for adaptive tracking (%) to assess visuo-motor control and vigilance

    Time frame: Several timepoints on Day 1; for up to 24 hours post-dose

  3. Change from baseline for body sway (antero-posterior in mm / 2 min) to assess postural stability

    Time frame: Several timepoints on Day 1; for up to 24 hours post-dose

  4. Change from baseline for visual analog scales (VAS) Bond & Lader to assess subjective alertness, mood, and calmness

    Time frame: Several timepoints on Day 1; for up to 24 hours post-dose

  5. Change from baseline for VAS for alcohol intoxication to assess subjective effects of ethanol

    Time frame: Several timepoints on Day 1; for up to 24 hours post-dose

  6. ACT-541468 PK endpoints for treatments A and B: Area under the plasma concentration-time curve (AUC) from time zero to 24 h (AUC0-24)

    Time frame: Several timepoints from Day 1 to Day 2 (EOT/EOS); for up to 24 hours post-dose

  7. ACT-541468 PK endpoints for treatments A and B: AUC from zero to infinity (AUC0-∞)

    Time frame: Several timepoints from Day 1 to Day 2 (EOT/EOS); for up to 24 hours post-dose

  8. ACT-541468 PK endpoints for treatments A and B: Maximum plasma concentration (Cmax)

    Time frame: Several timepoints from Day 1 to Day 2 (EOT/EOS); for up to 24 hours post-dose

  9. ACT-541468 PK endpoints for treatments A and B: Time to reach Cmax (tmax)

    Time frame: Several timepoints from Day 1 to Day 2 (EOT/EOS); for up to 24 hours post-dose

  10. ACT-541468 PK endpoints for treatments A and B: Terminal elimination half-life (t½)

    Time frame: Several timepoints from Day 1 to Day 2 (EOT/EOS); for up to 24 hours post-dose

  11. Ethanol PK endpoints for treatments A and C: Breath ethanol concentrations (BrEC)

    Time frame: Several timepoints on Day 1; for up to 24 hours post-dose

  12. Ethanol PK endpoints for treatments A and C: Total ethanol dose (in grams) required to maintain the 0.6 g/L ethanol clamp

    Time frame: Several timepoints on Day 1; for up to 5 hours

  13. Safety endpoints: Treatment-emergent AEs from study treatment administration up to EOT in each treatment period

    Time frame: AEs from Day 1 to Day 2 (EOT/EOS); for up to 2 days post-dose

  14. Safety endpoints: Treatment-emergent SAEs from study treatment administration up to EOT in each treatment period

    Time frame: SAEs from Screening to Safety follow up; for up to 14 weeks

Sponsors and collaborators

Lead sponsor

Idorsia Pharmaceuticals Ltd.

Industry

Registry information

Official study title

A Double-blind, Randomized, Placebo-controlled, Double-dummy, Four-way Crossover Study to Investigate the Drug-drug Interactions Between ACT-541468 and Ethanol in Healthy Subjects

Important dates

Study start
2018
Primary completion
2018
Study completion
2018
First posted
Aug 1, 2018
Registry last updated
Oct 15, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.